EUVIMEDAtklāt EUVIMED
Klinische Studie (Phase I)Multizentrische StudieOpen access · CC BY 4.0

Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD ‐1 and VEGF , in Chinese Patients With Advanced Solid Tumors

Fenghua Wang, Xiaoli Wei, Yulong Zheng, Jing Wang, Jieer Ying, Xiaozhong Chen, Suxia Luo, Huiyan Luo iD, Xufang Yu iD, Benchao Chen, Lei Ma, Ruihua Xu iD

Cancer Medicine · 2025-03 · 14 (6)

DOI: 10.1002/cam4.70653 ↗

At a glance

Klinische Studie (Phase I) in Cancer Medicine, published online on 2025-03-20. Written by Fenghua Wang and 11 co-authors. Institution: Department of Medical Oncology, Cancer Prevention Center, Sun Yat-Sen University, Guangzhou, Guangdong, China. Major MEDLINE topics: Antibodies, Bispecific, Neoplasms, Programmed Cell Death 1 Receptor, Vascular Endothelial Growth Factor A. Cited 14 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0). Funded by: Akeso Biopharma, Inc..

AbstraktsSubjectsBibliogrāfiskie datiCiteRelated studies

Abstract (original language)

Background

Ivonescimab (AK112) is a first‐in‐class bispecific antibody that simultaneously targets programmed death‐1 (PD‐1) and vascular endothelial growth factor (VEGF) with cooperative binding. We report the safety, pharmacokinetics (PK), and pharmacodynamics (PD) profiles of ivonescimab in patients suffered from advanced solid tumors.

Methods

A multicenter, open‐label, dose‐escalation, phase I study was conducted in five hospitals in China. Ivonescimab was used as a monotherapy. The dose of ivonescimab intravenously administered was 3, 5, 10, 20, and 30 mg/kg every 2 weeks (Q2W), and 10 and 20 mg/kg every 3 weeks (Q3W). Safety, PK, and PD of ivonescimab were evaluated.

Results

A total of 59 patients treated in the study. Only one dose‐limiting toxicity (DLT) occurred in 1 out of 9 patients in the 10 mg/kg Q2W cohort, indicating that no maximum tolerated dose was reached. Among the participants, 53 patients (89.8%) experienced treatment‐related adverse events (TRAEs), with the most common being proteinuria (33.9%), aspartate aminotransferase elevation (27.1%), white blood cell count decrease (22.0%), alanine aminotransferase elevation (20.3%), and anemia (20.3%). Fourteen patients (23.7%) had ≥ Grade 3 TRAEs, and 7 patients (11.9%) experienced serious TRAEs. Notably, there were no reported deaths associated with the TRAEs, and no dose‐dependent increase in adverse events was observed. The half‐life of ivonescimab ranged from 5.0 to 7.3 days following single‐dose administration across all dose levels. The serum concentrations of ivonescimab increased with escalating doses in an approximately dose‐proportional manner. Following multiple doses, the accumulation ratio ranged from 1.1 to 1.7, suggesting mild accumulation of ivonescimab. The steady state was achieved after 5 doses. Ivonescimab occupancy on PD‐1 sustained over 80% across the treatment period. Serum VEGF level was rapidly down‐regulated after each administration.

Conclusions

In patients with advanced solid tumors, ivonescimab monotherapy was well‐tolerated and demonstrated a linear PK characteristics. PD profiles showed the promising potential of ivonescimab for the management of advanced solid tumors. Trial Registration: ClinicalTrials.gov (NCT04597541)

Subjects

MeSH terms (MEDLINE)

Antibodies, BispecificNeoplasmsProgrammed Cell Death 1 ReceptorVascular Endothelial Growth Factor AAdultAgedFemaleHumansMaleMiddle AgedChinaDose-Response Relationship, DrugMaximum Tolerated DoseEast Asian People

Author keywords

AK112PD‐1VEGFadvanced solid tumorsivonescimabpharmacodynamicspharmacokinetics

Substances

Antibodies, BispecificPDCD1 protein, humanProgrammed Cell Death 1 ReceptorVascular Endothelial Growth Factor AVEGFA protein, human

Authors and institutions

  • Department of Medical Oncology, Cancer Prevention Center, Sun Yat-Sen University, Guangzhou, Guangdong, China.
  • Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
  • Department of Gynecology, Hunan Cancer Hospital, Changsha, Hunan, China.
  • Department of Hepatobiliary Pancreatic Gastric Medicine, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China.
  • The Department of Head and Neck Radiation, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China.
  • Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, Henan, China.

ORCID profiles: Huiyan Luo, Xufang Yu, Ruihua Xu

Funding

  • Akeso Biopharma, Inc.

Cite

APA

Wang, F., Wei, X., Zheng, Y., Wang, J., Ying, J., Chen, X., Luo, S., Luo, H., Yu, X., Chen, B., Ma, L., & Xu, R. (2025). Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD ‐1 and VEGF , in Chinese Patients With Advanced Solid Tumors. Cancer Medicine, 14(6). https://doi.org/10.1002/cam4.70653

Vancouver

Wang F, Wei X, Zheng Y, Wang J, Ying J, Chen X, et al. Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD ‐1 and VEGF , in Chinese Patients With Advanced Solid Tumors. Cancer Medicine. 2025;14(6). doi:10.1002/cam4.70653

BibTeX
@article{Wang2025,
  author = {Wang, Fenghua and Wei, Xiaoli and Zheng, Yulong and Wang, Jing and Ying, Jieer and Chen, Xiaozhong and Luo, Suxia and Luo, Huiyan and Yu, Xufang and Chen, Benchao and Ma, Lei and Xu, Ruihua},
  title = {Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD ‐1 and VEGF , in Chinese Patients With Advanced Solid Tumors},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {6},
  doi = {10.1002/cam4.70653}
}
Start for free →